NCT00654680View on ClinicalTrials.gov

Evaluating the Efficacy and Safety of Vardenafil in Patients Erectile Dysfunction Solely Secondary to Spinal Cord Injury

PHASE3CompletedINTERVENTIONAL
Enrollment

418

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

January 31, 2004

Study Completion Date

January 31, 2004

Conditions
Erectile Dysfunction
Interventions
DRUG

Vardenafil (Levitra, BAY38-9456)

5mg, 10mg or 20mg taken 1 hour prior to sexual intercourse

DRUG

Placebo

Matching placebo

Sponsors

Lead Sponsor

Bayer

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Bayer

INDUSTRY

NCT00654680 - Evaluating the Efficacy and Safety of Vardenafil in Patients Erectile Dysfunction Solely Secondary to Spinal Cord Injury | Biotech Hunter | Biotech Hunter